Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Angioplasty | Atrial Fibrillation | Bleeding | Cardiology | Congestive Heart Failure | Coronary Angioplasty | Drugs & Pharmacology | Health Insurance | Heart | Heart Disease | Heart Failure | Hemorrhagic Stroke | Insurance | Ischemic Stroke | Liver | Liver Disease | Percutaneous Coronary Intervention | Stroke | Study | Thrombosis | Universities & Medical Training | Urology & Nephrology | Vitamin K | Vitamins